Valuation: Dyne Therapeutics, Inc.

Market Cap 3.03B 2.67B 2.53B 2.29B 4.3B 290B 4.34B 30.32B 11.69B 148B 11.37B 11.12B 477B P/E 2026 *
-4.47x
P/E 2027 * -4.81x
Enterprise Value 2.26B 1.99B 1.89B 1.71B 3.21B 217B 3.24B 22.62B 8.72B 111B 8.48B 8.29B 356B EV / Sales 2026 *
-
EV / Sales 2027 * 48.8x
Free-Float
98.33%
Yield 2026 *
-
Yield 2027 * -
1 day-0.80%
1 week-5.43%
Current month-36.26%
1 month-35.34%
3 months-23.75%
6 months-5.43%
Current year-17.13%
1 week 15.63
Extreme 15.63
16.76
1 month 15.63
Extreme 15.63
26.18
Current year 14
Extreme 14
27.3
1 year 12.33
Extreme 12.3335
27.3
3 years 6.36
Extreme 6.36
47.45
5 years 4.3
Extreme 4.3
47.45
10 years 4.3
Extreme 4.3
47.45
Manager TitleAgeSince
Chief Executive Officer 63 2024-03-24
Director of Finance/CFO 58 2025-03-30
Chief Tech/Sci/R&D Officer - 2025-04-27
Director TitleAgeSince
Director/Board Member 62 2018-10-31
Chairman 56 2018-10-31
Director/Board Member 51 2018-10-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/8/26 Sell

Executive/Senior Manager

-185 0.0001%
9/8/26 Sell

Chief Technology Officer

-1,290 0.0007%
9/8/26 Sell

Chief Executive Officer

-5,658 0.0030%
Change 5-day change 1-year change 3-year change Capi.($)
-0.80%-5.43%+31.04%+80.92% 3.05B
-0.70%-4.28%+52.62%+86.42% 71.81B
+0.45%-0.82%+38.81%+84.19% 60.06B
+2.34%+3.60%+33.48%+23.06% 27.93B
-1.73%-4.30%-18.37%+357.94% 25.7B
-0.51%-2.28%+0.48%-9.27% 24.89B
+0.65%+1.67%+26.47%-7.62% 20.92B
+3.46%+3.02%+158.90%+337.81% 15.04B
+0.48%+0.86%+44.56%+168.42% 14.46B
+0.34%-1.74%-7.67%+503.82% 13.87B
Average +0.39%-1.70%+36.03%+162.57% 27.77B
Weighted average by Cap. +0.21%-1.87%+36.59%+127.70%

Financials

2026 *2027 *
Net sales - 52.79M 46.59M 44.08M 39.97M 74.94M 5.07B 75.68M 529M 204M 2.59B 198M 194M 8.32B
Net income -643M -568M -537M -487M -914M -61.74B -923M -6.45B -2.48B -31.53B -2.42B -2.36B -101B -658M -580M -549M -498M -934M -63.1B -943M -6.59B -2.54B -32.22B -2.47B -2.42B -104B
Net Debt -769M -679M -642M -583M -1.09B -73.83B -1.1B -7.71B -2.97B -37.7B -2.89B -2.83B -121B -449M -396M -375M -340M -637M -43.06B -643M -4.49B -1.73B -21.99B -1.68B -1.65B -70.76B
Logo Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy and preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease. Its product candidate, zeleciment basivarsen (also known as DYNE-101), is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, zeleciment rostudirsen (also known as DYNE-251), is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to skipping exon 51. Its other product candidates are DYNE-302 and DYNE-401.
Employees
289
Date Price Change Volume
26-09-29 US$16.21 -0.80% 2,289,048
26-09-28 US$16.34 +1.93% 2,306,034
26-09-25 US$16.03 -2.91% 1,612,918
26-09-24 US$16.51 +1.73% 3,197,693
26-09-23 US$16.23 -5.31% 2,636,264
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
16.21USD
Average target price
37.20USD
Spread / Average Target
+129.49%

Quarterly revenue - Rate of surprise